News
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet
Why Rocket Lab Stock Fell Out of Orbit in September
The pristine two-year track record of successful launches by Rocket Lab USA (NASDAQ: RKLB) went up in smoke in September, and the rocket wasn't the only thing that crashed. Shares of Rocket Lab fell
Rocket Lab Just Reminded Us: Accidents Can Happen
40, 36, 1.
Space is hard, as the saying goes. Since its very first rocket launch from Launch Complex 1 in New Zealand, small rocket company Rocket Lab USA (NASDAQ: RKLB) has attempted 40 separate
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) are seeing explosive gains in Tuesday's trading following an announcement that the company is on track to be acquired by Alfasigma, a private
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far
Why CymaBay Therapeutics Stock Is Sinking This Week
Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The decline
EQS-News: Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK
UN Chief Warns of 'Great Fracture' Among Global Powers
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.
As the United
Why Rocket Lab Stock Got Rocked Today
Shares of American-New Zealand space company Rocket Lab USA (NASDAQ: RKLB) plunged 15.5% at the open on Tuesday after the company's 41st attempt at a rocket launch ended in failure this morning.
The
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Other than running out of money, what economic risk do Intellia Therapeutics, (NASDAQ: NTLA) CRISPR Therapeutics, (NASDAQ: CRSP) Bluebird Bio, (NASDAQ: BLUE) and a bunch of other cutting-edge
You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10
It's best not to go all in on high-risk stocks, but that doesn't mean you should avoid them entirely. If you can tolerate some risk, certain players could make a good addition to a diversified
Why Shares of Scilex Are Dropping Monday
Shares of Scilex (NASDAQ: SCLX) were down more than 14% as of 1 p.m. ET on Monday, despite the company announcing positive phase 2 trial results for its non-opioid pain therapy SP-103. The healthcar
Why Shares of ImmunityBio Jumped This Week
Shares of ImmunityBio (NASDAQ: IBRX) were up more than 30% for the week as of 10 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday
Aclaris Therapeutics (NASDAQ: ACRS) had a fine Thursday, at least as far as its stock was concerned. The biotech's shares enjoyed a nearly 6% lift in price, thanks largely to a generous price-target
Novavax Is a Step Behind, Again. Should You Be Worried?
In the earliest days of the coronavirus vaccine race, Novavax (NASDAQ: NVAX) stood out as a potential winner. As a result, investors bet on the company and drove up its share price more than 2,700%
Up 20% in 1 Month, Is This Stock a Buy?
The pandemic isn't over -- much as we might wish it were. An ongoing surge in coronavirus cases is pouring cold water on these hopes. We recently got a stark reminder that the disease spares nobody
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
The hot-streak biotech stock of the moment, CymaBay Therapeutics (NASDAQ: CBAY), again rose in price on Tuesday. That extends the company's winning streak on the market following the impressive
2 No-Brainer Biotech Stocks to Buy Right Now
Biotech stocks are a great way to grow your portfolio over time -- you can get in early on an innovator and benefit as it brings exciting candidates through the pipeline to commercialization. Of
EQS-News: Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin
Why CymaBay Therapeutics Stock Popped Again Today
For the third day in a row, shares of CymaBay Therapeutics (NASDAQ: CBAY) enjoyed a very healthy gain in price. That came on the announcement of a capital-raising effort by the company. Ultimately
Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double
Cathie Wood is known for her propensity to buy growth stocks that have the chance to disrupt their industries while also making early investors rich. And that means she's a big buyer of biotech
Why Shares of Insmed Are Soaring This Week
Shares of Insmed (NASDAQ: INSM) were up more than 17% for the week as of 10:30 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last
Why CymaBay Therapeutics Stock Is Jumping Today
Shares of CymaBay Therapeutics (NASDAQ: CBAY) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday.
The continued momentum is a result of
Why Coherus BioSciences Stock Was Plunging This Week
Live by the index, die by the index -- being included in a well-known collection of stocks can really help a company's visibility and boost investor morale. The opposite effect can kick in if it
EQS-News: Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo